15 Nov 2021
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
20 Jun 2022
Greater Manchester patients to benefit from revolutionary cholesterol-lowering treatment
Health Innovation Manchester hosted a workshop to develop the pathway for a revolutionary new cholesterol-lowering drug in Greater Manchester.
The cutting-edge new treatment, Inclisiran, is used to treat people with high cholesterol who have a history of cardiovascular disease. It reduces the risk of heart attacks and strokes and has the potential to save lives.
People living in deprived areas of the UK are four times more likely to die from premature cardiovascular disease compared to less deprived areas. This treatment could be a game-changer for communities within Greater Manchester.
Health Innovation Manchester hosted the event on June 14th 2022 to understand the needs of patients and the system. We welcomed 37 delegates including patients, GPs, cardiovascular specialists and pharmacists.
Muzammal Iqbal, a Greater Manchester resident, shared his story with delegates:
‘I was greatly relieved and happy when I heard about Inclisiran. Before having that first injection, I was living in fear. What if I had a stroke? What if I had another cardiac arrest? What would happen to my family? […] I feel that I am being supported in a more proactive way now.’
The event was facilitated by Jay Hamilton, Interim Chief Officer at Health Innovation Manchester. Speakers included Ben Bridgewater, Chief Executive at Health Innovation Manchester, Dr Jaydeep Sarma, Lead Cardiologist at Manchester Foundation Trust, and Saif Ahmed, GP at Millbrook Medical Practice.
Following the event, a task and finish group will be set up to accelerate the adoption of Inclisiran within Greater Manchester.
Inclisiran is delivered as an injection twice a year and so offers a convenient alternative to pills. It can be used alongside statins, adding to the options available to patients to help control their cholesterol levels.
The Academic Health Science Network, including Health Innovation Manchester, is supporting the adoption of Inclisiran as part of a broader national lipid management programme. This aligns with the NHS Long Term Plan’s ambition of reducing cardiovascular deaths and disease.
For more information on Lipids and Inclisiran join a panel of motivational speakers at an upcoming virtual event hosted by Novartis
Virtual Event: Let’s Discuss Lipids in Manchester
Date: Thursday 30th June 2022
Time: 19:00 – 20:30